Cytotoxicity of psammaplin A from a two-sponge association may correlate with the inhibition of DNA replication
Creators
- 1. School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016 (China)
- 2. College of Pharmacy, Pusan National University, Pusan 609-735, S (Korea, Republic of)
- 3. Department of Chemistry and Biohealth Product Research Center, Inje University, Kimhae 621-749, S (Korea, Republic of)
- 4. Department of Chemistry, Pusan National University, Pusan, 609-735, S (Korea, Republic of)
- 5. Department of Microbiology, Inje University, Kimhae 621-749, S (Korea, Republic of)
- 6. Department of Medical Laboratory Science, Inje University, Kimhae 621-749, S (Korea, Republic of)
Description
SV40 DNA replication system is a very useful tool to understand the mechanism of replication, which is a tightly regulated process. Many environmental and cellular factors can induce cell cycle arrest or apoptosis by inhibiting DNA replication. In the course of our search for bioactive metabolites from the marine sponges, psammaplin A was found to have some anticancer properties, the possible mechanism of which was studied. Cell viability was determined by Cell Counting Kit-8 (CCK-8) to count living RAW264.7 cells by combining 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl) -2H-tetrazolium (WST-8) and 1-methoxy-phenazine methosulfate (1-methoxy-PMS). The effect of psammaplin A on DNA replication was carried out in SV40 DNA replication system in vitro. The activities of topoisomerase I and polymerase α-primase were measured by the relaxation of superhelical plasmid DNA and the incorporation of [3H]dTTP to the template respectively. The ssDNA binding activity of RPA was assessed by Gel Mobility Shift Assay (GMSA). We have found that psammaplin A delivers significant cytotoxic activity against the RAW264.7 cell line. It was also found that psammaplin A could substantially inhibit SV40 DNA replication in vitro, in which polymerase α-primase is one of its main targets. Taken together, we suggest that psammaplin A-induced cytotoxicity may correlate with its inhibition on DNA replication. Psammaplin A has the potential to be developed as an anticancer drug
Availability note (English)
Available from http://dx.doi.org/10.1186/1471-2407-4-70; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC524492Additional details
Identifiers
Publishing Information
- Journal Title
- BMC cancer (Online)
- Journal Volume
- 4
- Journal Page Range
- p. 70
- ISSN
- 1471-2407
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 46082248
- Subject category
- S60: APPLIED LIFE SCIENCES; S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- APOPTOSIS; CELL CYCLE; DNA; DNA REPLICATION; GELS; IN VITRO; INHIBITION; LIVER; METABOLITES; PHENAZINE; TETRAZOLIUM; VIABILITY
- Descriptors DEC
- AZINES; AZOLES; BODY; CHLORIDES; CHLORINE COMPOUNDS; COLLOIDS; DIGESTIVE SYSTEM; DISPERSIONS; GLANDS; HALIDES; HALOGEN COMPOUNDS; HETEROCYCLIC COMPOUNDS; NUCLEIC ACID REPLICATION; NUCLEIC ACIDS; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; ORGANS; PYRAZINES; TETRAZOLES
Optional Information
- Copyright
- Copyright (c) 2004 Jiang et al
- Notes
- PMCID: PMC524492; PUBLISHER-ID: 1471-2407-4-70; PMID: 15456519; OAI: oai:pubmedcentral.nih.gov:524492; licensee BioMed Central Ltd.